North America Autoinjectors Market Size By Product Type (Disposable Auto-Injectors, Reusable Auto-Injectors), By Application (Rheumatoid Arthritis, Anaphylaxis), By End User (Home Care Settings, Hospitals & Clinics), By Geographic Scope And Forecast

North America Autoinjectors Market Size And Forecast

North America Autoinjectors Market size was valued at USD 341.02 Million in 2023 and is projected to reach USD 931.41 Million by 2030, growing at a CAGR of 13.48% from 2024 to 2030.

Surge in demand driven by rising cases of chronic conditions, emphasizing the need for efficient and convenient drug delivery and accelerated adoption of auto-injectors due to an increased focus on patient-centric healthcare solutions, and enhancing treatment adherence are the factors driving the market growth. The North America report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

North America Autoinjectors Market Definition

Autoinjectors are self-injectable devices; they are a type of medical device that may administer medications subcutaneously or intramuscularly. They include prefilled syringes or cartridges that are propelled by a spring mechanism. The main advantages of this device are ease of use, greater patient compliance, less anxiety, and dose accuracy. Immediate therapy for emergencies such as anaphylaxis, migraine, and status epilepticus, as well as chronic illnesses such as psoriasis, diabetes, multiple sclerosis, and rheumatoid arthritis Reformulation of first-generation biologics, technological breakthroughs, novel designs, patient compliance, and overwhelming interest in self-administration all contributed to the widespread usage of autoinjectors.

An autoinjector is a medical device that is meant to provide a patient with a pre-measured amount of medication in a simple and efficient manner. This unique instrument has transformed medicine administration, giving a user-friendly alternative for those who need to self-administer injections or for healthcare professionals looking for a simplified manner of administering exact amounts. The fundamental function of an autoinjector is to make injection administration more accessible and less daunting for patients. It consists of a syringe pre-filled with the prescribed drug, an injection needle, and an automated medication delivery mechanism. Autoinjectors’ user-friendly design has shown to be very advantageous for people suffering from chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis, and various allergic reactions.

The simplicity of usage of autoinjectors is one of its main advantages. Many patients find the traditional approach of extracting medication from a vial and self-injecting to be intimidating and prone to mistakes. Autoinjectors reduce the need for manual manipulation of syringes and vials, lowering the risk of dosage mistakes and allowing a more regulated and consistent administration of medication. This is especially relevant for drugs with limited therapeutic windows, where precision dosage is critical for maximum performance and safety.

North America Autoinjectors Market Overview

Autoinjectors, also known as self-injection devices, are meant to make medicine administration easier by allowing patients to self-administer prescription pharmaceuticals in a safe and user-friendly way. The autoinjector is a game-changing medical gadget that has transformed the way injectable drugs are administered. Its user-friendly design, safety features, and adaptability make it a useful tool for patients with chronic diseases and healthcare providers looking for fast and dependable medicine administration systems. Autoinjectors are anticipated to evolve further as product type and medical research advance, strengthening their significance in modern healthcare. Autoinjectors have been a major innovation in medical product type, providing a simple and effective method of pharmaceutical administration. These products have had a considerable influence on many medical markets across the world, including the North American region.

The North America Autoinjectors Market is a thriving and vital business in the healthcare industry. The North America Autoinjectors Market has grown dramatically in recent years, owing to a mix of product type breakthroughs, increased chronic illness incidence, and a growing emphasis on patient-centric drug delivery systems. The rising prevalence of chronic conditions such as diabetes, rheumatoid arthritis, multiple sclerosis, and anaphylaxis is one of the key drivers of the autoinjector market in North America. Because these disorders frequently necessitate regular and accurate medicine delivery, autoinjectors are a popular choice among both healthcare practitioners and patients. Autoinjectors’ simplicity of use and lower chance of dose mistakes contribute to their widespread acceptance. Technological advancements have played a critical role in improving the functioning and safety of autoinjectors. Automatic needle insertion, dosage management, and computerized tracking systems have all contributed to the devices’ increased appeal among both patients and healthcare providers.

Regulatory factors also play an important role in determining the autoinjector market landscape. Stringent regulatory procedures for these devices’ clearance may hinder their debut, hurting market development. To effectively bring their inventions to market, companies in this field must negotiate complicated regulatory systems. The incorporation of smart product types into autoinjectors is one of the market’s major trends. Connecting smart autoinjectors to mobile applications allows patients and healthcare practitioners to track and monitor drug adherence. This link improves patient participation while also providing useful data for personalized healthcare management. Looking into the future, the North America Autoinjectors Market is expected to expand more. The ongoing development of biological medications, as well as the rising frequency of chronic illnesses, will fuel demand for enhanced drug delivery methods. To achieve expanded market access, manufacturers are required to focus on product innovation, resolving affordability issues, and partnering with healthcare stakeholders.

North America Autoinjectors MarketSegmentation Analysis

The North America Autoinjectors Market is Segmented on the basis of Product Type, Application, End User, and Geography.

North America Autoinjectors Market, By Product Type

• Disposable Auto-Injectors
• Reusable Auto-Injectors

To Get a Summarized Market Report By Product Type-

Based on Product Type, the market is bifurcated into Disposable Auto-Injectors and Reusable Auto-Injectors. Disposable auto-injectors accounted for the largest market share of 89.39% in 2022, with a market value of USD 304.83 Million, and is projected to grow at a CAGR of 13.79% during the forecast period. Reusable auto-injector was the second-largest market in 2022, valued at USD 36.18 Million in 2022; it is projected to grow at a CAGR of 10.51%.

North America Autoinjectors Market, By Application

• Rheumatoid Arthritis
• Anaphylaxis
• Multiple Sclerosis
• Diabetes
• Others

To Get a Summarized Market Report By Application-

Based on Application, the market is bifurcated into Rheumatoid Arthritis, Anaphylaxis, Multiple Sclerosis, Diabetes, and Others. Rheumatoid Arthritis accounted for the largest market share of 32.63% in 2022, with a market value of USD 111.28 Million and is projected to grow at the highest CAGR of 13.28% during the forecast period. Anaphylaxis was the second-largest market in 2022, valued at USD 90.91 Million in 2022; it is projected to grow at a CAGR of 14.92%.

North America Autoinjectors Market, By End User

• Home Care Settings
• Hospitals & Clinics
• Others

Based on End User, the market is bifurcated into Home Care Settings, Hospitals & Clinics, and Others. Home Care Settings accounted for the largest market share of 57.05% in 2022, with a market value of USD 194.55 Million, and is projected to grow at a CAGR of 14.77% during the forecast period. Hospitals & Clinics was the second-largest market in 2022, valued at USD 101.55 Million in 2022; it is projected to grow at a CAGR of 12.14%.

North America Autoinjectors Market, By Geography

• U.S.
• Canada
• Mexico

On the basis of Regional Analysis, the North America Autoinjectors Market is classified into U.S., Canada, and Mexico. US accounted for the largest market share of 74.46% in 2022, with a market value of USD 253.91 Million and is projected to grow at a CAGR of 13.64% during the forecast period. Canada was the second-largest market in 2022, valued at USD 59.11 Million in 2022; it is projected to grow at a CAGR of 12.60%.

Key Players

The “North America Autoinjectors Market” study report will provide valuable insight with an emphasis on the North America market. The major players in the market are Amgen Inc., Eli Lilly and Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, Novartis International AG, Pfizer Inc., Sanofi, Johnson & Johnson, Becton Dickinson and Company (BD), Antares Pharma, SHL Medical AG, Ypsomed AG, Owen Mumford, Kaleo, Inc., Regeneron Pharmaceuticals Inc., and UCB.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with Coating Type benchmarking and SWOT analysis.

Key Developments

• In Febraury 2023, Amgen and AstraZeneca announced today that the FDA has approved TEZSPIRE (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 and older with severe asthma. TEZSPIRE, which was approved by the FDA in December 2021, is the only biologic approved for severe asthma that does not have any phenotypic (eosinophilic or allergic) or biomarker limitations within its approved label.
• In October 2022, BD collaborated with Biocorp on Injay technology, which adds connectivity to prefilled syringes. It is anticipated that it will help BD track adherence to self-administered injectable medications.
• In May 2022, Mounjaro (tirzepatide) injection, Eli Lilly and Company’s new once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, has been approved by the US Food and Drug Administration (FDA). Mounjaro has not been researched in people with a history of pancreatitis and is not recommended for type 1 diabetes mellitus patients.
• In April 2020, Teva Pharmaceutical Industries Ltd. stated that the AJOVY (fremanezumab-vfrm) autoinjector device is now accessible in the United States. The only anti-CGRP (calcitonin gene-related peptide) preventive migraine medicine with quarterly (675 mg) and monthly (225 mg) subcutaneous dose options, AJOVY, is authorized for th